Molecular mechanisms of steroid hormone action
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The ability of oestrogens and androgens to stimulate the growth of a number of endocrine cancers is well established and several endocrine therapies are widely used to reduce the availability of the hormones or to block their action. These include non-steroidal hormone antagonists such as tamoxifen and flutamide, steroidal compounds which include ICI 182780 and cyproterone acetate, and both steroidal and non-steroidal aromatase inhibitors. Although we have learned a great deal about the molecular mechanism of steroid hormone action, it is still unclear as to how hormones stimulate the proliferation of tumour cells and how hormone antagonists function. In part this is a result of the ability of oestradiol and testosterone to regulate the expression of many proteins implicated in the control of cell proliferation making it difficult to identify the crucial targets. Some of these targets are growth factors and/or their receptors which suggests that the mitogenic effects of steroids may be mediated by indirect autocrine or paracrine mechanisms (Clarke et al. 1991, Roberts and Sporn 1992). Alternatively since steroids regulate the expression of certain cyclins or kinase inhibitors (Musgrove and Sutherland 1994, Altucci et al. 1996) they may control cell cycle progression directly. Recent work suggests that as well as the cyclin D1 gene, cyclin D1 itself may be a crucial target (Zwijsen et al. 1997) but additional proteins could also be important in different subsets of tumours. The identification of target genes for steroid hormones is further complicated by the observation that receptor signalling is cross-coupled with that of other signalling pathways. It used to be thought that signalling by receptors was relatively straightforward compared with most other signalling pathways, since the receptor itself is a transcription factor. It is now clear however, that growth factors, neurotransmitters and other hormones are able to modulate the activity of steroid hormone receptors (Power et al. 1991, Aronica and Katzenellenbogen 1993, Ignar-Trowbridge et al. 1993 ). This means that alterations in the activity of receptors and the expression of individual target genes involved in cell proliferation is determined not only by hormonal signals but also by changes in other signalling pathways, which undoubtedly take place during breast and prostate cancer progression. Receptors are also capable of regulating the activity of a number of other transcription factors, either directly or indirectly, and thereby modulate the ability of other signalling pathways to control gene transcription (Shemshedini et al. 1991, Philips et al. 1993, Stein and Yang 1995, Webb et al. 1995). Although the precise role of steroid hormones in cell proliferation is still ill-defined, tremendous progress has been made in elucidating the role of hormones in receptor activation and the mechanism by which hormone antagonists block this activity. In particular two recent advances have been made which provide new insights into steroid hormone action and the function of nuclear receptors in general. Firstly, models for the three-dimensional structure of the ligand binding domain of several receptors have been determined (Bourguet et al. 1995, Renaud et al. 1995, Wagner et al. 1995) and secondly, novel proteins have been identified (Halachmi et al. 1994, Cavaillés et al. 1994) which interact with receptors in a ligand dependent manner and may play a role in gene transcription. These developments are helping to provide a better understanding of the mechanism of action of both hormones agonists and antagonists and the links between nuclear receptors and other signalling pathways. In this review we will outline these advances, with reference to the oestrogen receptor, and discuss their relevance to antioestrogen therapy and tamoxifen resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964 · cited 7×
“In contrast, a second group of nuclear receptors, including the retinoic acid receptor (RAR), thyroid hormone receptor (TR) and vitamin D receptor, bind to DNA as heterodimers in combination with the retinoid X receptor (RXR) (Mangelsdorf et al. 1995).”
BackgroundMethodInfluentialKuiper, G. G. J. M., Carlsson, B., Grandien, K., Enmark, E., Häggblad, J., Nilsson, S., & Gustafsson, J.-A. (1997) · Endocrinology · doi:10.1210/endo.138.3.4979 · Cited by 4,442
Gene regulation by steroid hormones
Beato, M. (1989) · Cell · doi:10.1016/0092-8674(89)90237-7 · Cited by 3,383
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355 · cited 2×
“…structure of the ligand binding domain of several receptors have been determined (Bourguet et al. 1995, Renaud et al. 1995, Wagner et al. 1995, Brzozowski et al. 1997) and secondly, novel proteins have been identified (Cavaillès et al. 1994, Halachmi et al. 1994) which interact with receptors…”
BackgroundERβ: Identification and characterization of a novel human estrogen receptor
Mosselman, S., Polman, J., & Dijkema, R. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00782-x · Cited by 2,269 · cited 1×
“Androgen receptors are encoded by a single gene whereas there are two genes for ERs, ERα and ERβ (Kuiper et al. 1996, Mosselman et al. 1996).”
BackgroundKamei, Y., Xu, L., Heinzel, T., Torchia, J., Kurokawa, R., Gloss, B., Lin, S.-C., Heyman, R. A., Rose, D. W., Glass, C. K., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81118-6 · Cited by 2,150
A signature motif in transcriptional co-activators mediates binding to nuclear receptors
Heery, D. M., Kalkhoven, E., Hoare, S., & Parker, M. G. (1997) · Nature · doi:10.1038/42750 · Cited by 2,128 · cited 1×
“For example two related proteins, N-CoR and SMRT, which function as repressors for RXR and TR in the absence of ligand (Horlein et al. 1995, Heinzel et al. 1997, Nagy et al. 1997), have been reported to bind to oestradiol and progesterone receptors in the presence of antagonists (Jackson et al.…”
BackgroundSelf-citationActivation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964 · cited 2×
“The activation of ERs by EGF has been analysed in cell lines (Ignar-Trowbridge et al. 1993, 1996) and shown to be mediated by the MAP kinase pathway which phosphorylates a serine residue at position 118 in AF1 (Ali et al. 1993, Kato et al. 1995, Bunone et al. 1996).”
BackgroundSteroid Receptor Interactions with Heat Shock Protein and Immunophilin Chaperones*
Pratt, W. B., & Toft, D. O. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.3.0303 · Cited by 1,791
Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase
Nagy, L., Kao, H.-Y., Chakravarti, D., Lin, R. J., Hassig, C. A., Ayer, D. E., Schreiber, S. L., & Evans, R. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80218-4 · Cited by 1,230 · cited 1×
“…related proteins, N-CoR and SMRT, which function as repressors for RXR and TR in the absence of ligand (Horlein et al. 1995, Heinzel et al. 1997, Nagy et al. 1997), have been reported to bind to oestradiol and progesterone receptors in the presence of antagonists (Jackson et al. 1997, Smith et…”
Background
Cited by
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
Couse, J. F., & Korach, K. S. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0370 · Cited by 2,045
Heemers, H. V., & Tindall, D. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0019 · Cited by 753
The Estrogen Receptor β Subtype: A Novel Mediator of Estrogen Action in Neuroendocrine Systems
Kuiper, G. G. J. M., Shughrue, P. J., Merchenthaler, I., & Gustafsson, J.-Å. (1998) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1998.0170 · Cited by 439
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
Osborne, C. K., Wakeling, A., & Nicholson, R. I. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601629 · Cited by 414
“…control is mediated via two regions of the ERdesignated activation functions AF1 and AF2, which recruit other proteins such as transcriptional co-activators and co-repressors to the transcriptional complex (Beato, 1989; Tsai and O’Malley, 1994; Horwitz et al, 1996; White and Parker, 1998).”
BackgroundThe role of steroids in follicular growth
Drummond, A. E. (2006) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-4-16 · Cited by 366
Plasma Membrane Estrogen Receptors Exist and Functions as Dimers
Razandi, M., Pedram, A., Merchenthaler, I., Greene, G. L., & Levin, E. R. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0115 · Cited by 330
Bidirectional Signaling between the Estrogen Receptor and the Epidermal Growth Factor Receptor
Levin, E. R. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0368 · Cited by 329
Glucocorticoid and thyroid hormone receptors in mitochondria of animal cells
Scheller, K., Seibel, P., & Sekerist, C. E. (2003) · International review of cytology · doi:10.1016/s0074-7696(02)22011-2 · Cited by 73
20-Hydroxyecdysone protects wheat seedlings (Triticum aestivum L.) against lead stress
Lamhamdi, M., Lafont, R., Rharrabe, K., Sayah, F., Aarab, A., & Bakrim, A. (2016) · Plant Physiology and Biochemistry · doi:10.1016/j.plaphy.2015.11.006 · Cited by 18
Metadata
- Authors
- White, R.
- Venue
- Endocrine Related Cancer
- Publisher
- Bioscientifica
- Published
- 1998-03-01
- Volume
- 5
- Issue
- 1
- Pages
- 1-14
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2170447445
- Cited by
- 138
- References
- 14
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.